help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, P.
Right arrow Articles by Simon, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, P.
Right arrow Articles by Simon, D.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 3505-3512, Copyright © 1996 by Endocrine Society


ARTICLES

Selective recognition of M235T angiotensinogen variants and their determination in human plasma by monoclonal antibody-based immunoanalysis

P Cohen, G Badouaille, AP Gimenez-Roqueplo, JC Mani, TT Guyene, X Jeunemaitre, J Menard, P Corvol, B Pau and D Simon
Sanofi Recherche, Montpellier, France.

The common M235T mutation of human angiotensinogen has been shown to be associated with a 10-20% increase in plasma angiotensinOgen level and increased frequency of essential and pregnancy-induced hypertension. The detection of such a common factor in the plasma of individuals at risk could be a useful tool for modern molecular-based medicine. The recognition of M235T variants was investigated using four monoclonal antibodies (mAbs) directed against human angiotensinogen; two immunometric assays were developed. The first assay (using mAbS 7B2 and 4G3) allowed the direct determination of angiotensinogen concentrations and did not show a significant difference with the enzymatic measurement of angiotensinogen. The second assay (using mAbs 1H8 and 1C11) showed a fine distinction between the T235 mutant and M235 wild- type forms of angiotensinogen, with a greater affinity for the latter, as confirmed by biosensor BIAcore experiments. This assay was extremely sensitive in measuring the proportions of the M235 and T235 forms present in the test samples, the first time such a distinction has been achieved in the serpin family. The simple immunoanalysis of the plasma allowed the direct determination of the M235T genotype of the individual tested. Furthermore, it was shown that the T174M mutation, described as being in complete linkage disequilibrium with the M235T mutation, had no influence on these results. Moreover, this assay suggested the presence of the M235 and T235 angiotensinogens in approximately equal amounts in heterozygous plasmas. In conclusion, the immunometric assay described in this study should provide original tools for investigating the relationship between M235T genotype, plasma angiotensinogen levels, and regulation of blood pressure.


This article has been cited by other articles:


Home page
Physiol. GenomicsHome page
B. Cvetkovic, H. L. Keen, X. Zhang, D. Davis, B. Yang, and C. D. Sigmund
Physiological significance of two common haplotypes of human angiotensinogen using gene targeting in the mouse
Physiol Genomics, December 3, 2002; 11(3): 253 - 262.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
R. Rauramaa, R. Kuhanen, T. A. Lakka, S. B. Vaisanen, P. Halonen, M. Alen, T. Rankinen, and C. Bouchard
Physical exercise and blood pressure with reference to the angiotensinogen M235T polymorphism
Physiol Genomics, August 14, 2002; 10(2): 71 - 77.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Celerier, G. Schmid, J.-P. Le Caer, A.-P. Gimenez-Roqueplo, D. Bur, A. Friedlein, H. Langen, P. Corvol, and X. Jeunemaitre
Characterization of a Human Angiotensinogen Cleaved in Its Reactive Center Loop by a Proteolytic Activity from Chinese Hamster Ovary Cells
J. Biol. Chem., March 31, 2000; 275(14): 10648 - 10654.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Corvol, A. Persu, A.-P. Gimenez-Roqueplo, and X. Jeunemaitre
Seven Lessons From Two Candidate Genes in Human Essential Hypertension : Angiotensinogen and Epithelial Sodium Channel
Hypertension, June 1, 1999; 33(6): 1324 - 1331.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A.-P. Gimenez-Roqueplo, J. Celerier, G. Schmid, P. Corvol, and X. Jeunemaitre
Role of Cysteine Residues in Human Angiotensinogen. CYS232 IS REQUIRED FOR ANGIOTENSINOGEN-PRO MAJOR BASIC PROTEIN COMPLEX FORMATION
J. Biol. Chem., December 18, 1998; 273(51): 34480 - 34487.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A.-P. Gimenez-Roqueplo, J. Celerier, G. Lucarelli, P. Corvol, and X. Jeunemaitre
Role of N-Glycosylation in Human Angiotensinogen
J. Biol. Chem., August 14, 1998; 273(33): 21232 - 21238.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
P. Corvol and X. Jeunemaitre
Molecular Genetics of Human Hypertension: Role of Angiotensinogen
Endocr. Rev., October 1, 1997; 18(5): 662 - 677.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society